NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...

LOS ANGELES, CA / ACCESS Newswire / February 4, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action on behalf of purchasers of securities of Novo Nordisk A/S between November 2, 2022 and December 19, 2024, ...

Novo’s Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

You have until March 10, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you are an investor who purchased or otherwise acquired Novo securities during the Class Period. A ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

Cumberland Pharmaceuticals' Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...